A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Pfizer has made an internal business decision to not continue further development of PF-07284890. This decision was not due to major safety concerns or requests from any regulatory authorities.

Conditions

Malignant Melanoma
Carcinoma, Non-Small-Cell Lung
Brain Neoplasms, Primary
Brain Neoplasms
Malignant Neoplasms

Interventions

DRUG: PF-07284890
DRUG: Binimetinib
DRUG: Midazolam

Sponsor

Pfizer